Kodiak Sciences Inc.

NASDAQ:KOD

Biotechnology

Healthcare
$97.81 -0.08%

-$0.03 today

Market cap
$6.40B
Beta
2.21
P/E (TTM)
-9.6
EPS (TTM)
-$3.73
52W Low $3.43High $47.84

Volume 0.74M

Average 1.10M

KOD Interest Expense

Cost of servicing the company's debt during the period.

Kodiak Sciences Inc.NASDAQ: KOD

Interest Expense · Q3 FY2026 · quarter ended Sep 2026

Interest expense remains negative

Q3 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How KOD compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
KOD Competitors
Interest Expense for KOD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$396M USD-7.0%+43.5%7.4%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$55.4M USD+51.4%-9.7%0.4%
OCULOcular Therapeutix, Inc.LTM Mar 2026$11.63M USD-7.1%+19.0%22.3%
OCGNOcugen, Inc.LTM Mar 2026$5.02M USD+449.6%—112.5%
OCSOculis Holding AGLTM Mar 2026CHF 801.45K CHF-5.0%-50.2%159.0%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$313.51K USD—-42.5%94.1%
KODKodiak Sciences Inc.LTM Sep 2026$0 USD———
BLTEBelite Bio, IncLTM Sep 2026$0 USD———
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding KOD) —-6.0%-9.7%14.9%

Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue8.71M11M25.95M26.71M0
Gross Profit(8.71M)(11M)(25.95M)(26.71M)0
Gross Margin—————
Research & Development217.34M267.59M206.3M126.1M182.37M
Selling, General & Admin41M62.79M71.02M34.05M52.02M
Operating Expenses258.34M330.38M251.37M160.14M234.39M
Depreciation & Amortization8.71M11M25.95M26.71M26.32M
EBITDA(258.26M)(322.8M)(234.53M)(149.5M)(203.65M)
EBITDA Margin—————
Operating Income(267.05M)(341.38M)(277.32M)(186.85M)(234.39M)
Operating Margin—————
Interest Income298K7.07M16.73M11.15M4.52M
Interest Expense22K18K13K00
Other Income / Expenses61K7.56M16.83M10.64M4.42M
Income Before Tax(266.99M)(333.82M)(260.49M)(176.21M)(229.97M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(266.99M)(333.82M)(260.49M)(176.21M)(229.97M)
Net Margin—————
EPS (Basic)(5.16)(6.39)(4.97)(3.35)(4.32)
EPS (Diluted)(5.16)(6.39)(4.97)(3.35)(4.32)
Weighted Avg Shares51.79M52.25M52.41M52.58M53.21M
Weighted Avg Shares (Diluted)51.79M52.25M52.41M52.58M53.21M

Kodiak Sciences Inc.

NASDAQ:KOD

Intrinsic Alpha fair value

Locked

Current Price

$97.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.